In a strategic move to expand its specialty biopharmaceuticals portfolio, Meitheal Pharmaceuticals has acquired the North American rights to CONTEPO\u2122 (fosfomycin for injection) from Nabriva Therapeutics. The announcement, made on July 18, 2024, marks a significant step in Meitheal’s efforts to address the growing concern of antibiotic resistance.<\/p>\n
CONTEPO\u2122, a novel intravenous antibiotic, has shown promising results against multi-drug resistant (MDR) strains that cause complicated urinary tract infections (cUTI). With its unique mechanism of action, CONTEPO\u2122 could potentially fill critical gaps in the current antibiotic treatment landscape.<\/p>\n
Tom Shea, Chief Executive Officer of Meitheal, emphasized the strategic importance of this acquisition, stating, “The addition of CONTEPO\u2122 to our robust product portfolio provides us with a novel therapeutic with the potential to address a significant unmet need around increasing antibiotic resistance.”<\/p>\n
Key points of the acquisition include:<\/p>\n
The acquisition of CONTEPO\u2122 adds to Meitheal’s growing portfolio of specialty biopharmaceuticals, following their commercial licensing agreement for XTMAB-16 in 2023. As a fully integrated biopharmaceutical company, Meitheal is well-positioned to navigate the final stages of the regulatory process and, if approved, ensure a consistent supply of this innovative antibiotic.<\/p>\n
With an estimated three million cases of Gram-negative cUTIs treated annually in U.S. hospitals, and approximately 40% suspected to be caused by resistant strains, CONTEPO\u2122 could play a crucial role in addressing this serious health threat.<\/p>\n
As antibiotic resistance continues to pose challenges in healthcare, Meitheal’s acquisition of CONTEPO\u2122 represents a significant step towards providing new treatment options for patients with complicated urinary tract infections.<\/p>\n
Read the press release on Business Wire<\/a><\/p>\n \u2014-<\/p>\n